Form 4: Edwards Lifesciences CFO Scott Ullem Executes Stock Option and Sells Shares Under 10b5-1 Plan

Scott Ullem, CFO of Edwards Lifesciences, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• On February 13, 2025, Scott B. Ullem, the Chief Financial Officer of Edwards Lifesciences Corp, executed a transaction involving the company's stock.
• Ullem exercised employee stock options to acquire 11,250 shares of common stock at a price of $45.2767 per share.
• Simultaneously, Ullem sold 11,250 shares of common stock at a weighted average price of $75.7575 per share.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 19, 2024.
• Following these transactions, Ullem directly owns 30,561 shares of common stock and indirectly owns 266,318 shares through a trust.
• Ullem also directly owns 33,750 derivative securities in the form of employee stock options.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing stock transactions by a company executive. It doesn't inherently convey positive or negative sentiment, as it simply reports facts.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies. The use of 10b5-1 plans allows insiders to sell shares over a period of time, mitigating concerns about trading on material non-public information. These transactions are closely watched by investors for insights into management's perspective on the company's value.

Comparison to Industry Standards

• Executive compensation packages often include stock options and restricted stock units to align management's interests with those of shareholders.
• The use of 10b5-1 trading plans is a standard practice among corporate executives to manage their personal finances while avoiding accusations of insider trading.
• Comparable companies in the medical device industry, such as Medtronic and Abbott, also see regular Form 4 filings related to executive stock transactions.

Stakeholder Impact

• The transactions may have a minor impact on shareholders, as the sale of shares by an executive can sometimes be interpreted as a lack of confidence in the company, although the 10b5-1 plan mitigates this concern.

Key Dates